Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer, Lymphoma, and Other Types of Cancer) - Global Opportunity Analysis and Industry Forecast 2017-2023.

LI_171467
Pages: 152
Sep 2017 | 2025 Views
face gplus_n
Author's : Onkar Sumant and Gaurav Phalke
Tables: 45
Charts: 37
twit_n pr_n

Antibody Drug Conjugates Market Overview:

Antibody Drug Conjugates Market are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. ADC’s are designed to eliminate cancer cells only without harming the normal cells. This is a major advantage of ADC’s as the unharmed healthy cells enable patients to recover faster. The antibody drug conjugates market was valued at $1,387 million in 2016, and is estimated to reach $3,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023.

Global Antibody Drug Conjugates Market Segmentation

GLOBAL ANTIBODY DRUG CONJUGATES MARKET SEGMENTATION

The report segments the market based on drugs, technology, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is classified into CD30 antibodies and HER2 antibodies. Based on application, the market is categorized into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Increase in prevalence of cancer worldwide and unhealthy urban lifestyle and surge in consumption of tobacco and alcohol across geographies pose as major cancer risk factors. According to National Cancer Institute “the number of people living beyond cancer diagnosis is expected to reach approximately 19 million by 2024.” Increase in demand for cost-effective and quality cancer treatment is expected to drive the ADC’s market during the study period.

Global Antibody Drug Conjugates Market, by Geography, 2016 (% Share)

GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY, 2016 (% SHARE)

The report provides extensive competitive analysis and profiles of key market players, such as, include F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Immunomedics, Inc., Progenics Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals.

The other players in the value chain include Agensys, Inc., Concortis Biotherapeutics, Sanofi S.A., Celldex Therapeutics Inc., and Synthon Holding B.V.

Key Benefits :

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography assists to understand the regional market and the strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the antibody drug conjugates market.

Antibody Drug Conjugates Market Key Segments:

By Drugs

  • Adcetris
  • Kadcyla

By Mechanism Of Action

  • CD30 Antibodies
  • HER2 Antibodies

By Application

  • Breast Cancer
  • Lymphoma

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • The Netherlands
    • Norway
    • Russia
    • Sweden
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • New Zealand
    • Taiwan
    • Thailand
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Chile
    • Columbia
    • Egypt
    • Iran
    • Israel
    • Turkey
    • Venezuela
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region

3.5. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS

4.1. OVERVIEW

4.1.1. Market size & forecast

4.2. ADCETRIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast

4.3. KADCYLA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast

Chapter: 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION

5.1. OVERVIEW

5.1.1. Market size & forecast

5.2. CD30 ANTIBODIES

5.2.1. Market size & forecast

5.3. HER2 ANTIBODIES

5.3.1. Market size & forecast

Chapter: 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size & forecast

6.2. BREAST CANCER

6.2.1. Market size & forecast

6.3. LYMPHOMA

6.3.1. Market size & forecast

Chapter: 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.5. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.5. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. PFIZER, INC.

8.1.1. Operating business segments
8.1.2. Business performance

8.2. CELLDEX THERAPEUTICS INC.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. SEATTLE GENETICS INC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. GENENTECH INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. IMMUNOGEN INC.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.5. SANOFI S.A.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.7. IMMUNOMEDICS, INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. PROGENICS PHARMACEUTICALS INC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.8. BAYER HEALTHCARE PHARMACEUTICALS

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.10. SYNTHON HOLDING B.V.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 2. ADCETRIS ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. KADCYLA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 5. CD30 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. HER2 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 8. BREAST CANCER ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. LYMPHOMA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 13. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 14. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 16. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 17. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 22. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)
TABLE 24. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)
TABLE 25. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)
TABLE 26. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 27. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 28. CELLDEX THERAPEUTICS INC: COMPANY SNAPSHOT
TABLE 29. CELLDEX THERAPEUTICS INC: PRODUCT PORTFOLIO
TABLE 30. SEATTLE GENETICS INC: COMPANY SNAPSHOT
TABLE 31. SEATTLE GENETICS INC: PRODUCT PORTFOLIO
TABLE 32. GENENTECH INC: COMPANY SNAPSHOT
TABLE 33. GENENTECH INC: PRODUCT PORTFOLIO
TABLE 34. IMMUNOGEN INC: COMPANY SNAPSHOT
TABLE 35. IMMUNOGEN INC: PRODUCT PORTFOLIO
TABLE 36. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 37. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 38. IMMUNOMEDICS, INC: COMPANY SNAPSHOT
TABLE 39. IMMUNOMEDICS, INC: PRODUCT PORTFOLIO
TABLE 40. PROGENICS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 41. PROGENICS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 42. BAYER HEALTHCARE PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 43. BAYER HEALTHCARE PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 44. SYNTHON HOLDING B.V.: COMPANY SNAPSHOT
TABLE 45. SYNTHON HOLDING B.V.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. ANTIBODY DRUG CONJUGATES MARKET: MARKET SEGMENATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL DNA SEQUENCING MARKET, BY APPLICATION
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP PLAYER POSITIONING: GLOBAL ANTIBODY DRUG CONJUGATES MARKET
FIGURE 7. PATENT ANALYSIS BY YEAR
FIGURE 8. PATENT ANALYSIS BY REGION
FIGURE 9. BARGAINING POWER OF BUYERS
FIGURE 10. BARGAINING POWER OF SUPPLIERS
FIGURE 11. THREAT OF NEW ENTRANTS
FIGURE 12. THREAT OF SUBSTITUTION
FIGURE 13. COMPETITIVE RIVALRY
FIGURE 14. ANTIBODY DRUG CONJUGATES MARKET: DRUGS SEGMENATION
FIGURE 15. ANTIBODY DRUG CONJUGATES MARKET: MECHANISM OF ACTION SEGMENATION
FIGURE 16. ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION SEGMENATION
FIGURE 17. U.S. ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 18. CANADA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 19. MEXICO ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 20. GERMANY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 21. FRANCE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 22. UK ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 23. ITALY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 24. SPAIN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 25. REST OF EUROPE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 26. JAPAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 27. CHINA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 28. AUSTRALIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 29. INDIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH KOREA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 31. TAIWAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 33. BRAZIL ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 34. TURKEY ANTIBODY DRUG CONJUGATES MARKET, 2016-20223 ($MILLION)
FIGURE 35. SAUDI ARABIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 36. SOUTH AFRICA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)
FIGURE 37. REST OF LAMEA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

 

Antibody drug conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. Globally, in 2012 there were around 14.1 million cancer cases reported as per the data provided by the Cancer Research UK. The antibody drug conjugate market exhibits massive potential in the near future owing to the increase in prevalence of cancer across geographies. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market. Increase in demand from underdeveloped countries for cost-effective and efficient cancer treatment medication is further expected to boost the ADC’s market during the forecast period. Moreover, unhealthy urban lifestyle increases the risk of various diseases and surge in reported incidences of cancer is likely to fuel the demand of ADC’s in the study period.

Kadcyla is expected to account for largest market share in 2016 Owing to high prevalence of breast cancer while Adcetris is expected to grow at the highest rate during 2017-2023. In 2016, the breast cancer segment accounts for largest market share in the application area due to high number of reported cases of breast cancer globally.

North America accounted for major market share in the global ADC’s market in 2016 owing to high adoption of ADC’s and substantial purchasing power of the patient populace in the region. European region demonstrates somewhat similar potential and is reported to be the second largest ADCs market on the global platform. Asia-Pacific and LAMEA are expected to offer lucrative opportunities to market players in the near future. Countries, such as Brazil, India, China, and few others, are expected to pose as lucrative investment destinations for manufacturers of ADCs.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Antibody Drug Conjugates Market- Global Opportunity Analysis and Industry Forecast 2017-2023.

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo